![](/img/cover-not-exists.png)
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study
Bringeland, Gerd Haga, Myhr, Kjell-Morten, Vedeler, Christian Alexander, Gavasso, SoniaVolume:
415
Journal:
Journal of the Neurological Sciences
DOI:
10.1016/j.jns.2020.116880
Date:
August, 2020
File:
PDF, 161 KB
2020